Skip to main content

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Genentech, Inc.

Start Date

January 3, 2018

End Date

December 19, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Genentech, Inc.

Start Date

January 3, 2018

End Date

December 19, 2022